25468-67-1

Upstream product

• 459-31-4 3-(4-fluorophenyl)propanoic acid 
• 772-70-3 3-(4-fluorophenyl)propanoyl chloride 
• 459-32-5 (E)-4-fluorocinnamic acid 
• 405-99-2 para-fluorostyrene 
• 201230-82-2 carbon monoxide 
• 77287-34-4 formamide 
• 459-57-4 4-fluorobenzaldehyde 
• 136265-10-6 ethyl 4-fluorocinnamate 

Downstream Products

• 25468-86-4 3-(4'-fluorophenyl)propanenitrile 
• 46459-22-7 2-(4-fluoro-phenethyl)-5,6-dihydro-4H-[1,3]thiazine 
• 101488-65-7 3-(4-fluorophenyl)propan-1-amine 
• 852660-37-8 N-((1R,2S)-2-{[tert-butoxycarbonyl[3-(4-fluorophenyl)propyl]amino]methyl}cyclohexyl)-N'-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]urea 
• 852660-36-7 (1R,2S)-2-({tert-butoxycarbonyl-[3-(4-fluorophenyl)-propyl]amino}-methyl)-cyclohexylamine 
• 852660-32-3 N-((1R,2S)-2-{[[3-(4-fluorophenyl)propyl]amino]methyl}cyclohexyl)-N'-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]urea 
• 852661-55-3 N-((1R,2S)-3-{ethyl[3-(4-fluorophenyl)propyl]amino}-2-hydroxy-1-methylpropyl)-N'-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]urea 
• 852661-54-2 (2S,3R)-3-amino-1-{ethyl[3-(4-fluorophenyl)propyl]amino}butan-2-ol 

Relevant academic research and scientific papers

Identification of 2,6-Disubstituted 3 H-Imidazo[4,5- b]pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells

Dysferlinopathies, which are muscular diseases caused by mutations in the dysferlin gene, remain serious medical problems due to the lack of therapeutic agents. Herein, we report the design, synthesis, and structure-activity relationships of a 2,6-disubst

Visible-Light Decatungstate/Disulfide Dual Catalysis for the Hydro-Functionalization of Styrenes

We describe an efficient photoredox system, relying on decatungstate/disulfide catalysts, for the hydrofunctionalization of styrenes. In this methodology the use of disulfide as a cocatalyst was shown to be crucial for the reaction efficiency. This photoredox system was employed for the hydro-carbamoylation, -acylation, -alkylation, and -silylation of styrenes, giving access to a large variety of useful building blocks and high-value molecules such as amides and unsymmetrical ketones from simple starting materials.

Palladium-catalyzed regiodivergent hydroaminocarbonylation of alkenes to primary amides with ammonium chloride

Palladium-catalyzed hydroaminocarbonylation of alkenes for the synthesis of primary amides has long been an elusive aim. Here, we report an efficient catalytic system which enables inexpensive NH4Cl to be utilized as a practical alternative to gaseous ammonia for the palladium-catalyzed alkene-hydroaminocarbonylation reaction. Through appropriate choice of the palladium precursors and ligands, either branched or linear primary amides can be obtained in good yields with good to excellent regioselectivities. Primary mechanistic studies were conducted and disclosed that electrophilic acylpalladium species were capable of capturing the NH2-moiety from ammonium salts to form amides in the presence of CO with NMP as a base.

Primary fatty acid amide preparation method

The present invention provides a primary fatty acid amide preparation method. According to the present invention, under the action of a single auxiliary agent phosphine-containing transition metal catalyst or a combined auxiliary agent comprising a phosphine-free transition metal catalyst and a phosphine-containing ligand, terminally substituted olefin or cyclo-olefin, carbon monoxide and an ammonium salt are subjected to a hydrogen carboamidation reaction so as to prepare the primary fatty acid amide compound in one step; the raw material and the catalyst of the reaction are inexpensive and easy to obtain, and the synthesis process is simple, such that the synthesis cost is substantially reduced; the preparation method has characteristics of mild reaction condition and high yield, and issuitable for industrial production; and the raw material and the catalyst of the reaction are clean, non-toxic and low environment pollution.

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

Disclosed are a compound having cardiotonic activity and a pharmaceutical composition containing the same, and the composition containing the compound, according to the present invention, is useful for preventing and treating heart failure.COPYRIGHT KIPO 2016

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists

Conformational analysis of the 3-benzylpiperidine in CCR3 antagonist clinical candidate 1 (BMS-639623) predicts that the benzylpiperidine may be replaced by acyclic, conformationally stabilized, anti-1,2-disubstituted phenethyl- and phenpropylamines. Ab i

N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of chemokine receptors of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.